BR or R-CHOP induction followed by rituximab maintenance in transplant-ineligible patients with mantle cell lymphoma
Eva Hoster,
Katja Gutmair,
Nicholas Cunningham
et al.
Abstract:There are no studies directly comparing the efficacy of bendamustine with rituximab (BR) as induction therapy followed by maintenance rituximab (Rm) against rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) followed by Rm in previously untreated, older, transplant-ineligible patients with mantle cell lymphoma (MCL). The objective of this international study was to retrospectively compare the efficacy of these two treatment regimens by pooling and comparing a clinical trial cohort w… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.